1p2B5-Fc for COVID-19

c19early.org

COVID-19 Treatment Clinical Evidence

COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets. c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research. Only three high-profit early treatments are approved in the US. In reality, many treatments reduce risk, with 24 low-cost treatments approved across 163 countries.

Naso/oropharyngeal treatment Effective Treatment directly to the primary source of initial infection.
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.

1p2B5-Fc may be beneficial for COVID-19 according to the study below. COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 11,000+ potential treatments. c19early.org analyzes 210+ treatments. We have not reviewed 1p2B5-Fc in detail.

Study suggesting benefit with 1p2B5-Fc

Korobkova et al., Broadly neutralizing single-domain antibody targeting the spike NTD displays therapeutic efficacy against diverse SARS-CoV-2 variants, Frontiers in Immunology, doi:10.3389/fimmu.2026.1799333

The continuous evolution of SARS-CoV-2 virus has led to the emergence of multiple Omicron descendants resistant to previously approved therapeutic antibodies. Therefore, cross-reactive antibodies to conserved neutralizing epitopes are urgently needed to protect immunocompromised patients and individuals at high risk of severe COVID-19. Here we report the characterization of 1p2B5, a single-domain antibody targeting N-terminal domain (NTD) of SARS-CoV-2 S protein. 1p2B5 exerts broad neutralizing activity against diverse SARS-CoV-2 variants. The Fc-fused form of the antibody demonstrates enhanced neutralizing potency in vitro , inhibiting both the earliest and currently circulating subvariants with nanomolar activity. Systemic therapeutic administration of 1p2B5-Fc at a dose of 1 mg/kg protects Syrian hamsters and hACE2-transgenic mice from challenge with evolutionarily distant SARS-CoV-2 variants. Our findings highlight the potential of NTD-specific monoclonal antibodies for prophylaxis and therapeutic intervention.